Dr. Perez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Lebanon, NH 03756Phone+1 603-650-8626Fax+1 603-650-7791
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985
Certifications & Licensure
KS State Medical License 2011 - 2017
NH State Medical License 1998 - 2012
Clinical Trials
- A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Mar 01
- A Study in Advanced Solid Tumors Start of enrollment: 2010 Jun 01
- Study in Advanced Solid Tumors Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsDrug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.Takefumi Komiya, Satomi Yamamoto, Anuradha Roy, Peter R. McDonald, Raymond P. Perez
Translational Lung Cancer Research. 2017-10-01 - 85 citationsSoft tissue sarcomas in adultsConstantine P. Karakousis, Raymond P. Perez
CA. 1994-07-01 - 10 citationsPharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletionPatrick F. Smith, Brent M. Booker, Patrick J. Creaven, Raymond P. Perez, Lakshmi Pendyala
Journal of Clinical Pharmacology. 2003-12-01
Press Mentions
KU Cancer Center Makes Bid to Join Elite ClubSeptember 26th, 2016
Grant Support
- Protocol-Specific Research SupportNational Cancer Institute2009–2012
- Data And Safety MonitoringNational Cancer Institute2009–2012
- SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2010
- SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2009–2010
- Inhibition Of S14 By Conjugated Linoleic Acid In Advanced Solid Tumor PatientsNational Cancer Institute2009–2010
- Clinical ResearchNational Cancer Institute2004–2008
- Modulation Of Clinical Sensitivity To ChemotherapyNational Cancer Institute2000–2004
- Atorvastatin, A Prenylation Inhibitor In Acute Leukemia.National Cancer Institute2002–2003
Professional Memberships
- Member
- American Society of Pharmacology and Experimental Therapeutics - ASPETMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
